Annovis Bio (ANVS) announced the publication of a new article in a peer-reviewed journal Biomolecules, which describes the pharmacokinetic, PK, profile of a new crystal form of buntanetap and compares it to the old form across several studies including mice, dogs, and humans. The new crystal buntanetap is currently being used in the pivotal Phase 3 clinical trial in patients with early AD, which is actively enrolling participants across the U.S. The study is designed to deliver two key readouts: symptomatic and disease-modifying. Moreover, this new form extends the intellectual property protection of the Company’s lead compound into the 2040s, covering its mechanism of action, therapeutic use, and combination with other drugs.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Annovis Bio’s Promising Alzheimer’s Study: What Investors Need to Know
- Annovis Bio price target lowered to $10 from $12 at H.C. Wainwright
- Annovis Bio Reports Q2 2025 Progress and Financials
- Annovis Bio’s Promising Alzheimer’s Drug Trial: What Investors Need to Know
- Annovis Bio’s Strategic Advancements and Phase 3 Study Progress Support Buy Rating